Deutsche Bank initiates Regulus Therapeutics $RGLS with Buy, Target $30 http://www.benzinga.com/news/14/11/5032141/deutsche-bank-initiates-coverage-on-regulus-therapeutics-at-buy-announces-30-00-p There's a lot to like; platform, HCV, rare disease in 1 company. Data in HCV patients for RG-101 was compelling after 1 dose, more importantly it provided first validation for platform We see dramatic LT upside as this early platform story begins to play out If both RG-101 and RG-012 were successful, our Regulus FV is $99/share